Clairity has raised $43 million in Series B financing, which will be used to commercialize the company’s Clairity Breast and advance development of Clairity Breast 3D and Clairity Heart.
Clairity Breast, an AI platform that predicts a woman's five-year risk of breast cancer from routine mammograms, received de novo authorization from the U.S. Food and Drug Administration in 2025.
The company plans to expand its pipeline to include new AI-based predictive offerings for other major diseases. The funds will also support reimbursement initiatives and partnerships aimed at making Clairity Breast accessible across community imaging centers.
ACE Global Equity and Santé Ventures led the funding round, with continued participation from the Breast Cancer Research Foundation and several new investors. TCB Capital Advisors served as the exclusive financial adviser to Clairity with respect to the Series B financing.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
